This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ACE inhibitors in hypertension

Authoring team

ACE inhibitors are antihypertensive drugs. They are also used in the management of heart failure and chronic kidney disease.

Indications for the use of ACE inhibitors in the treatment of hypertension include:

  • compelling indications - heart failure, left ventricular dysfunction
  • possible indications - chronic renal disease*, type II diabetic nephropathy

Contraindications for the use of ACE inhibitors in the treatment of hypertension include:

  • compelling contraindications - pregnancy, renovascular disease
  • possible contraindications - renal impairment*, peripheral vascular disease**

ACE inhibitors are less effective when renin levels are low, most commonly seen in Afro-Caribbean hypertensive patients.

* ACE inhibitors may be beneficial in chronic renal failure but should be used with caution. Close supervision and specialist advice are needed when there is established and significant renal impairment.

** caution with ACE inhibitors and angiotensin II receptor antagonists in peripheral vascular disease because of association with renovascular disease.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.